The Global Liquid Biopsy in Cancer Diagnostics Market to Surpass USD 19 Billion by 2027 | DelveInsight

Las Vegas, USA, July 05, 2022 (GLOBE NEWSWIRE) — The Global Liquid Biopsy in Cancer Diagnostics Market to Surpass USD 19 Billion by 2027 | DelveInsight 

The liquid biopsy in cancer diagnostics market is expected to grow due to the rise in the burden of various cancers across the globe. Moreover, a growing preference for minimally invasive procedures among the population is also a factor contributing to the growth of liquid biopsy in the cancer diagnostics market.

DelveInsight’s Liquid Biopsy in Cancer Diagnostics Market Insights report provides the current and forecast market, forthcoming device innovation, individual leading companies’ market shares, challenges, liquid biopsy in cancer diagnostics market drivers, barriers, and trends, and key liquid biopsies companies in the market. 

Key Takeaways from the Liquid Biopsy in Cancer Diagnostics Market Report

• As per DelveInsight estimates, North America is anticipated to dominate the global liquid biopsy in cancer diagnostics market during the forecast period. 
• The leading liquid biopsy in cancer diagnostics companies such as Myriad Genetics Inc, Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc, Biocept Inc, Agilent Technologies Inc, MDx Health, Neogenomics Laboratories, F. Hoffman La Roche Ltd, Guardant Health,Bio-Techne, Illumina Inc, QIAGEN, Lucence Health Inc, Personal Gemone Diagnostics Inc, SAGA Diagnostics, Agena Bioscience Inc, The Menarini Group, MiRXES Pte Ltd., and several others are currently working in the liquid biopsy in cancer diagnostics market.
• In June 2021, NeoGenomics completed its acquisition of Inivata Ltd, a global, commercial-stage liquid biopsy platform-company headquartered in Cambridge, England.
• In January 2021, Exact Sciences Corporation acquired Thrive Earlier Detection Corp. (“Thrive”), a healthcare company dedicated to developing a blood-based, multi-cancer screening test.
• Thus, owing to such developments in the market, rapid growth will be observed in the liquid biopsy in cancer diagnostics market during the forecast period.

To read more about the latest highlights related to liquid biopsies cancer, get a snapshot of the key highlights entailed in the Global Liquid Biopsy Market Report

Liquid Biopsy 

Liquid biopsy is a test to detect tumor DNA that begins to circulate in blood after some tumor cells die and shed their genomic material. The Liquid biopsy test enables the diagnosis of tumors using only a blood or fluid sample rather than a solid tissue biopsy and thus is less invasive than a traditional biopsy. Liquid biopsy has the benefits of rapid, precise, real-time diagnosis.

The rising prominence of precision medicine in cancer care is one of the key factors responsible for a raised demand for liquid biopsies at present. The concept of precision medicine is considered a new approach to cancer management. The clinical applications of precision medicine are diverse, encompassing screening, diagnosis, prognosis, prediction of treatment response and resistance, early detection of recurrence/metastasis, and biologic cancer stratification. Liquid biopsies hold great promise for personalized medicine because they provide multiple non-invasive global snapshots of the primary and metastatic tumors. The customization of treatment specific to the patient’s health condition has gained widespread acceptance and attention from physicians. Liquid biopsy plays an important role in developing customized treatments for patients. It provides vital real-time information about the tumor profile and helps decide the subsequent steps in the treatment. 

Liquid Biopsy in Cancer Diagnostics Market Insights

Geographically, the global liquid biopsy in cancer diagnostics market is studied in North America, Europe, Asia-Pacific, and the Rest of the World. In terms of revenue share, North America currently leads the global market and is projected to hold its liquid biopsy in cancer diagnostics market position during the study period. This domination is owing to the growing government initiatives in the region to promote research in liquid biopsy and provide a conducive environment for liquid biopsy-related product development and their launches. 

To know more about why North America is leading the market growth in the liquid biopsy in cancer diagnostics market, get a snapshot of the Liquid Biopsy Market Trends

Liquid Biopsy in Cancer Diagnostics Market Dynamics

The global liquid biopsy in cancer diagnostics market is likely to observe a stellar growth due to the rising incidence of cancers, increase in demand for precision medicine, growing technical innovation in the product arena, and growing product approval of various liquid biopsy products for the detection of cancers, among others.

However, the risk of false results due to procedural limitations and lack of standardization of procedures may be challenging for liquid biopsy in cancer diagnostics market growth.

Moreover, the liquid biopsy in cancer diagnostics market witnessed a slump in generating revenue due to the implementation of various measures to curb the transmission of COVID-19 infection. The suspension of various elective surgeries and the outpatient visit was one of the major factors that reduced the demand for liquid biopsy products and services in the liquid biopsy in cancer diagnostics market as the healthcare system guidelines across the globe temporarily focused all their efforts on the management of COVID-19 infection patient load during the initial lockdown period. 

Get a sneak peek at the liquid biopsy in cancer diagnostics market dynamics @ Liquid Biopsy in Cancer Diagnostics Market Dynamics Analysis

Scope of the Liquid Biopsy in the Cancer Diagnostics Market Report

• Coverage: Global
• Study Period: 2019–2027
• Market Segmentation By Type: Product Type (Instruments and Reagents & Kits) and Services
• Market Segmentation By Sample Type: Blood, Urine, and Saliva
• Market Segmentation By Biomarker Type: Circulating Tumor Cells, Circulating Tumor DNA, Circulating Free DNA, and Others
• Market Segmentation By Cancer Type: Lung Cancer, Breast Cancer, Colon Cancer, and Others
• Market Segmentation By Technique: Polymerase Chain Reaction and Next Generation Sequencing
• Market Segmentation By End User: Hospitals, Diagnostic Centers, and Others
• Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World
• Key Liquid Biopsy in the Cancer Diagnostics Companies:  Myriad Genetics Inc, Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc, Biocept Inc, Agilent Technologies Inc, MDx Health, Neogenomics Laboratories, F. Hoffman La Roche Ltd, Guardant Health,Bio-Techne, Illumina Inc, QIAGEN, Lucence Health Inc, Personal Gemone Diagnostics Inc, SAGA Diagnostics, Agena Bioscience Inc, The Menarini Group, MiRXES Pte Ltd., among others
• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

DelveInsight Analysis: The liquid biopsy in cancer diagnostics market size is expected to grow at a CAGR of 16.64% to reach about USD 19.24 billion by 2027.

Which MedTech key players in the liquid biopsy in cancer diagnostics market are set to emerge as the trendsetter explore @ Liquid Biopsies Companies

Table of Contents 

Interested in knowing the liquid biopsy in cancer diagnostics market by 2027? Click to get a snapshot of the Cancer Diagnostics Market Outlook 

Related Reports

Oncology Drugs Market

Oncology Drugs Market Insight, Competitive Landscape, and Market Forecast, 2027 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key oncology drugs companies including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, among others.

Intratumoral Cancer Therapies Market

Intratumoral Cancer Therapies Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key intratumoral cancer therapies companies, including Daiichi Sankyo, Amgen, Idera Pharmaceuticals, among others.

Metastatic Breast Cancer Pipeline

Metastatic Breast Cancer Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key metastatic breast cancer companies, including Roche, RemeGen, SynCore Biotechnology, among others.

Metastatic Castration-Sensitive Prostate Cancer Market

Metastatic Castration-Sensitive Prostate Cancer Market Insight, Epidemiology, and Market Forecast, 2032 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key metastatic castration-sensitive prostate cancer companies including Astellas Pharma, Pfizer, Janssen Pharmaceutical, among others.

Small Cell Lung Cancer Pipeline

Small Cell Lung Cancer Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key small cell lung cancer companies, including Ascentage Pharma, Merck & Co, AstraZeneca, among others.

Related Healthcare Blogs

Upcoming Oncological Drugs in 2022
Metastatic Castration-Sensitive Prostate Cancer Treatment Market
Small Cell Lung Cancer Treatment Outlook

Related Cases Studies

Competitive Intelligence
Market Assessment
Product Assessment
Epidemiology Assessment

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  

Contact Us

Shruti Thakur 

[email protected] 

+1(919)321-6187 

https://www.delveinsight.com/medical-devices